Conference Set to Present the Latest Research and Developments on Cancer Health Disparities

When Michael Lawing was diagnosed with stage 3 renal cell carcinoma in 1997, he knew almost nothing about the disease.

Neither did his local urologist in rural North Carolina.

Within three years, Lawing’s cancer metastasized. His local doctor referred him to a specialist in Charlotte. Under his care, Lawing began a clinical trial of an immunotherapeutic drug. His cancer stabilized. Over the past two decades, he has experienced several recurrences of cancer, but a steady stream of newly approved treatments, most recently the immunotherapeutic Opdivo (nivolumab), have kept his disease under control. He is currently monitored with quarterly CT scans, but is taking no additional medication and experiences no symptoms or side effects.

Read More

FDA Approves a New PARP Inhibitor for BRCA-mutant Breast Cancer

In the midst of Breast Cancer Awareness Month, the US. Food and Drug Administration (FDA) provided good news for the breast cancer community this week when it approved a new breast cancer therapeutic called talazoparib (Talzenna), which targets ADP-ribose polymerase (PARP) proteins. They also approved a test to identify those patients eligible to receive talazoparib: patients with metastatic or locally advanced, HER2-negative breast cancer who have an inherited, cancer-associated BRCA1 or BRCA2 (BRCA1/2) mutation.

Read More

What is Convergence? How Can It Further Cancer Research?

The 30th Anniversary AACR Special Conference Convergence: Artificial Intelligence, Big Data, and Prediction in Cancer is focusing on a relatively new interdisciplinary field that seeks to further cancer research through the use of mathematics and computation, among other disciplines.

We had the opportunity to speak with both co-chairs about convergence and several areas of interest that will be discussed at the upcoming meeting, to be held Oct. 14-17 in Newport, Rhode Island.

Read More

September Editors’ Picks from AACR Journals

As a monthly feature on this blog, we spotlight the 10 articles selected by our editors from each journal issue published by the American Association of Cancer Research (AACR). These journals feature original articles spanning the continuum of cancer research, from basic science discoveries to patient care.

Read More

AACR Annual Meeting 2018: Off-the-shelf CAR T-cell Immunotherapy – Are we There Yet?

A study presented at the AACR Annual Meeting 2018 discussed preliminary data on an off-the-shelf, T-cell receptor (TCR)-less, dual-targeted CD19-CAR T-cell product, FT819. In proof-of-concept preclinical studies, FT819 was found …

Read More

AACR Annual Meeting 2018: Novel Immunotherapy Combinations to Combat Resistance to Checkpoint Inhibition

An exciting area in drug development, immunotherapy is being increasingly utilized by patients with different cancer types. These treatments work by stimulating the patient’s immune system to effectively target and …

Read More